Base de dados : MEDLINE
Pesquisa : D02.033.800.400.500 [Categoria DeCS]
Referências encontradas : 183 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 19 ir para página                         

  1 / 183 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:22902461
[Au] Autor:Ishiyama T; Jinguu A; Matsumoto H; Kikuchi J; Suzuki T; Yamakawa M
[Ad] Endereço:Dept. of Surgery, Yamagata Prefectural Shinjo Hospital, Japan.
[Ti] Título:[A case of adult primitive neuroectodermal tumor(PNET)with multiple lung metastases effectively treated with ADM, IFM(AI)regimen].
[So] Source:Gan To Kagaku Ryoho;39(8):1287-9, 2012 Aug.
[Is] ISSN:0385-0684
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:The patient was a 48-year-old male with a right subclavicular tumor. The pathological diagnosis showed primitive neuroectodermal tumor(PNET)because of the rosette formation and the positive neurogenic marker.Radiation was administered at a total dose of 50 Gy, because surgical resection would induce the loss of right arm function. CT examination demonstrated a reduction of the primary tumor and new multiple lung metastases. The patient received intravenous AI regimen(ADM and IFM). After the 7th course, both the primary tumor and multiple lung metastases decreased. AI regimen might be effective for PNET.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Neoplasias de Cabeça e Pescoço/tratamento farmacológico
Neoplasias Pulmonares/tratamento farmacológico
Tumores Neuroectodérmicos Primitivos/tratamento farmacológico
[Mh] Termos MeSH secundário: Biópsia por Agulha
Ácidos Borônicos/administração & dosagem
Bortezomib
Doxorrubicina/uso terapêutico
Neoplasias de Cabeça e Pescoço/patologia
Neoplasias de Cabeça e Pescoço/radioterapia
Seres Humanos
Neoplasias Pulmonares/secundário
Masculino
Melfalan/administração & dosagem
Meia-Idade
Mitolactol/uso terapêutico
Mitomicinas/uso terapêutico
Tumores Neuroectodérmicos Primitivos/patologia
Tumores Neuroectodérmicos Primitivos/radioterapia
Pirazinas/administração & dosagem
Terapia de Salvação
Suicídio
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:CASE REPORTS; ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Boronic Acids); 0 (Mitomycins); 0 (Pyrazines); 69G8BD63PP (Bortezomib); 80168379AG (Doxorubicin); LJ2P1SIK8Y (Mitolactol); Q41OR9510P (Melphalan)
[Em] Mês de entrada:1209
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120821
[St] Status:MEDLINE


  2 / 183 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:20221671
[Au] Autor:Mishra KK; Squire S; Lamborn K; Banerjee A; Gupta N; Wara WM; Prados MD; Berger MS; Haas-Kogan DA
[Ad] Endereço:Department of Radiation Oncology, University of California, San Francisco, 1600 Divisadero, San Francisco, CA 94143, USA.
[Ti] Título:Phase II TPDCV protocol for pediatric low-grade hypothalamic/chiasmatic gliomas: 15-year update.
[So] Source:J Neurooncol;100(1):121-7, 2010 Oct.
[Is] ISSN:1573-7373
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:To report long-term results for children with low-grade hypothalamic/chiasmatic gliomas treated on a phase II chemotherapy protocol. Between 1984 and 1992, 33 children with hypothalamic/chiasmatic LGGs received TPDCV chemotherapy on a phase II prospective trial. Median age was 3.0 years (range 0.3-16.2). Twelve patients (36%) underwent STRs, 14 (42%) biopsy only, and seven (21%) no surgery. Twenty patients (61%) had pathologic JPAs, nine (27%) grade II gliomas, and four (12%) no surgical sampling. Median f/u for surviving patients was 15.2 years (range 5.3-20.7); 20 of the 23 surviving patients had 14 or more years of follow-up. Fifteen-year PFS and OS were 23.4 and 71.2%, respectively. Twenty-five patients progressed, of whom 13 are NED, two are AWD, and 10 have died. All children who died were diagnosed and first treated at age three or younger. Age at diagnosis was significantly associated with relapse and survival (P = 0.004 for PFS and P = 0.037 for OS). No PFS or OS benefit was seen with STR versus biopsy/no sampling (P = 0.58 for PFS, P = 0.59 for OS). For patients with JPAs and WHO grade II tumors, the 15-year PFS was 18.8 and 22.2% (P = 0.95) and 15-year OS was 73.7 and 55.6% (P = 0.17), respectively. Upfront TPDCV for children with hypothalamic/chiasmatic LGGs resulted in 15-year OS of 71.2% and 15-year PFS of 23.4%. No survival benefit is demonstrated for greater extent of resection. Age is a significant prognostic factor for progression and survival.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Glioma/tratamento farmacológico
Neoplasias Hipotalâmicas/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Fatores Etários
Criança
Pré-Escolar
Progressão da Doença
Intervalo Livre de Doença
Feminino
Glioma/mortalidade
Seres Humanos
Neoplasias Hipotalâmicas/mortalidade
Lactente
Lomustina/uso terapêutico
Estudos Longitudinais
Masculino
Mitolactol/uso terapêutico
Valor Preditivo dos Testes
Procarbazina/uso terapêutico
Estudos Retrospectivos
Terapia de Salvação/métodos
Tioguanina/uso terapêutico
Resultado do Tratamento
Vincristina/uso terapêutico
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
35S93Y190K (Procarbazine); 5J49Q6B70F (Vincristine); 7BRF0Z81KG (Lomustine); FTK8U1GZNX (Thioguanine); LJ2P1SIK8Y (Mitolactol)
[Em] Mês de entrada:1101
[Cu] Atualização por classe:161019
[Lr] Data última revisão:
161019
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:100312
[St] Status:MEDLINE
[do] DOI:10.1007/s11060-010-0151-7


  3 / 183 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:19757193
[Au] Autor:Olasz L; Szalma J; Orsi E; Tornóczky T; Markó T; Nyárády Z
[Ad] Endereço:Department of Oral and Maxillofacial Surgery, University of Pécs, 7621, Pécs, Dischka Gy. u.5., Hungary. lajos.olasz@aok.pte.hu
[Ti] Título:Neoadjuvant chemotherapy: does it have benefits for the surgeon in the treatment of advanced squamous cell cancer of the oral cavity?
[So] Source:Pathol Oncol Res;16(2):207-12, 2010 Jun.
[Is] ISSN:1532-2807
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The purpose of this clinicopathological study was to evaluate the effects and efficiency of combined neoadjuvant chemotherapy related to surgical margin. 100 consecutively treated squamous cell cancer patients receiving a combined neoadjuvant therapy were selected (Bleomycin-Vincristin-Methotrexate (BVM) or BVM + Mitolactol or BVM + Cisplatin). After three courses of chemotherapy, the patients were operated on. The largest diameter of the primary tumors was compared before and after chemotherapy. In the surgical specimen, the involvement of surgical margin was assessed. The largest diameter before chemotherapy was: T2 30%; T3 55%; T4A 15%. After chemotherapy, the rest tumor was assessed in the surgical specimen as: no rest 11%; <2 cm 57%; 2-4 cm 28%; 4-6 cm 4%. The no rest and <2 cm (optimal operability) tumor was observed in T2: 94%; in T3: 73%; in the T4A: 0%. Severe side effects (Grade III-IV) were not observed. There was a significant decrease in size (P < 0.0001). Of the 100 surgical specimens, 83% had clear-, 9% close- and 8% involved margins. From T4A, there was a 40% (6 patients) involved margin. Based on the significantly better size and operability of primary T2-3, the mild side effects and the high (83%) percentage of clear surgical margins, that is better than other (without preoperative chemotherapy) results, sought the use of chemotherapy is recommended before surgery. Due to the 40% involved margin, we don't suggest surgery in T4A.
[Mh] Termos MeSH primário: Carcinoma de Células Escamosas/tratamento farmacológico
Carcinoma de Células Escamosas/cirurgia
Neoplasias Bucais/tratamento farmacológico
Neoplasias Bucais/cirurgia
[Mh] Termos MeSH secundário: Antineoplásicos/uso terapêutico
Protocolos de Quimioterapia Combinada Antineoplásica
Bleomicina
Cisplatino/administração & dosagem
Feminino
Seres Humanos
Masculino
Metotrexato
Meia-Idade
Mitolactol
Terapia Neoadjuvante
Estadiamento de Neoplasias
Procedimentos Cirúrgicos Bucais
Médicos
Cirurgia Bucal
Vincristina
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 11056-06-7 (Bleomycin); 5J49Q6B70F (Vincristine); LJ2P1SIK8Y (Mitolactol); Q20Q21Q62J (Cisplatin); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:1008
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:090917
[St] Status:MEDLINE
[do] DOI:10.1007/s12253-009-9208-3


  4 / 183 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:19951584
[Au] Autor:Song X; Wang JB; Yin DL; Yang HY; Liu LX; Jiang HC
[Ad] Endereço:Department of General Surgery, First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, China.
[Ti] Título:Down-regulation of lung resistance related protein by RNA interference targeting survivin induces the reversal of chemoresistances in hepatocellular carcinoma.
[So] Source:Chin Med J (Engl);122(21):2636-42, 2009 Nov 05.
[Is] ISSN:0366-6999
[Cp] País de publicação:China
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Both survivin and lung resistance related protein (LRP) are related to the chemoresistances in hepatocellular carcinoma (HCC). But the relationship between survivin and LRP is indefinite. The aim of this study was to investigate the effects of down-regulation of survivin on LRP expressions and the reversal of chemoresistances in HCC both in vitro and in vivo. METHODS: The expressions of survivin were detected by RT-PCR and Western blotting in HCC cell line SMMC-7721 and SMMC-7721/ADM. The sensitivities of these two cell lines to ADM were evaluated by MTT assays. SiRNA which targeted survivin was transfected into SMMC-7721/ADM cells, then the sensitivity of SMMC-7721/ADM cells to ADM and the expressions of survivin and LRP were detected respectively. SMMC-7721/ADM cells were transplanted subcutaneously into nude mice to establish xenograft tumors. Antitumor activities of RNA interference (RNAi) targeting survivin, various doses of ADM and combination therapies were observed respectively. Possible toxicities were evaluated. LRP expression changes were tested. Student's t test was used for evaluating statistical significance. RESULTS: The expressions of survivin in SMMC-7721/ADM cell line showed significant elevation compared to those in SMMC-7721 cell line (P < 0.05). Positive siRNA down-regulated the expressions of survivin significantly (P < 0.05). SiRNA targeting survivin could sensitize SMMC-7721/ADM cells to ADM and down-regulate the expressions of LRP significantly (P < 0.05). Growths of the tumors were significantly inhibited in positive siRNA group as compared with those in the control group from the 8th day (P < 0.05). Combination therapies caused significant tumor inhibitions compared with tumors of nude mice in the other three groups respectively (P < 0.05). No toxicities were found in nude mice treated by siRNA and combination therapies. The expressions of LRP were markedly reduced in tumors treated with siRNA targeting survivin (P < 0.05). CONCLUSIONS: Down regulation of survivin gene by RNAi can increase chemosensitivity of HCC both in vitro and in vivo. The reversal of drug resistance may be reduced through the inhibitions of LRP.
[Mh] Termos MeSH primário: Carcinoma Hepatocelular/tratamento farmacológico
Carcinoma Hepatocelular/metabolismo
Proteínas Associadas aos Microtúbulos/metabolismo
Interferência de RNA/fisiologia
RNA Interferente Pequeno/fisiologia
Partículas de Ribonucleoproteínas em Forma de Abóbada/metabolismo
[Mh] Termos MeSH secundário: Animais
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Western Blotting
Carcinoma Hepatocelular/genética
Linhagem Celular Tumoral
Doxorrubicina/uso terapêutico
Resistência a Medicamentos Antineoplásicos
Seres Humanos
Proteínas Inibidoras de Apoptose
Camundongos
Camundongos Endogâmicos BALB C
Camundongos Nus
Proteínas Associadas aos Microtúbulos/genética
Mitolactol/uso terapêutico
Mitomicinas/uso terapêutico
RNA Interferente Pequeno/genética
Reação em Cadeia da Polimerase Via Transcriptase Reversa
Partículas de Ribonucleoproteínas em Forma de Abóbada/genética
Ensaios Antitumorais Modelo de Xenoenxerto
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (BIRC5 protein, human); 0 (Inhibitor of Apoptosis Proteins); 0 (Microtubule-Associated Proteins); 0 (Mitomycins); 0 (RNA, Small Interfering); 0 (Vault Ribonucleoprotein Particles); 0 (major vault protein); 80168379AG (Doxorubicin); LJ2P1SIK8Y (Mitolactol)
[Em] Mês de entrada:1003
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:091203
[St] Status:MEDLINE


  5 / 183 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:19332100
[Au] Autor:Tsai HC; Yeh TL; Hsieh MH; Lee IH; Chen KC; Chen PS; Yang YK; Yao WJ
[Ad] Endereço:Department of Psychiatry, Hospital and College of Medicine, National Cheng Kung University, Tainan, Taiwan.
[Ti] Título:Association between serotonin transporter availability and overall rating scores of quality of life in healthy volunteers.
[So] Source:Prog Neuropsychopharmacol Biol Psychiatry;33(4):711-4, 2009 Jun 15.
[Is] ISSN:1878-4216
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Depression and impaired quality of life (QOL) are frequently observed in patients suffering from a variety of diseases. In addition, it has been reported that an enhanced degradation of the serotonin precursor tryptophan may contribute to QOL deterioration in some diseases. However, it is unclear whether the correlation between the QOL scores and the central serotonergic tone is only mediated by the severity of either the depression symptoms or the physical illness itself. The present study examined the relationship between serotonin transporter (SERT) availability and life quality as measured by the World Health Organization Quality of Life brief version questionnaire (WHO-QOL) in healthy participants in order to exclude the influence of depressive mood and disease. The SERT availability in the midbrain was approximated using SPECT with [(123)I] ADAM ligand in fifty-eight healthy volunteers. The overall rating sub scores of the WHO-QOL correlated positively with serotonin transporter availability in the males. Central serotoninergic activity may play a role in the overall rating scores of the WHO-QOL.
[Mh] Termos MeSH primário: Associação
Encéfalo/metabolismo
Nível de Saúde
Qualidade de Vida
Proteínas da Membrana Plasmática de Transporte de Serotonina/metabolismo
[Mh] Termos MeSH secundário: Adulto
Protocolos de Quimioterapia Combinada Antineoplásica/metabolismo
Encéfalo/diagnóstico por imagem
Doxorrubicina/metabolismo
Feminino
Seres Humanos
Isótopos de Iodo/metabolismo
Masculino
Mitolactol/metabolismo
Mitomicinas/metabolismo
Fatores Sexuais
Inquéritos e Questionários
Tomografia Computadorizada de Emissão de Fóton Único/métodos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Iodine Isotopes); 0 (Mitomycins); 0 (Serotonin Plasma Membrane Transport Proteins); 80168379AG (Doxorubicin); LJ2P1SIK8Y (Mitolactol)
[Em] Mês de entrada:0908
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:090401
[St] Status:MEDLINE
[do] DOI:10.1016/j.pnpbp.2009.03.018


  6 / 183 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:18248979
[Au] Autor:Hildebrand J; Gorlia T; Kros JM; Afra D; Frenay M; Omuro A; Stupp R; Lacombe D; Allgeier A; van den Bent MJ; EORTC Brain Tumour Group investigators
[Ad] Endereço:Hopital Universitaire Erasme, Brussels, Belgium.
[Ti] Título:Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882).
[So] Source:Eur J Cancer;44(9):1210-6, 2008 Jun.
[Is] ISSN:0959-8049
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: In a previous randomised EORTC study on adjuvant dibromodulcitol (DBD) and bichloroethylnitrosourea (BCNU) in adults with glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), a clinically significant trend towards a longer overall survival (OS) and a progression-free survival (PFS) was observed in the subgroup of AA. The aim of the present study was to test this adjuvant regimen in a larger number of AA patients. METHODS: Continuation of the previous phase III trial for newly diagnosed AA according to the local pathologist. Patients were randomised to either radiotherapy only or to radiotherapy in combination with BCNU on day 2 and weekly DBD, followed by adjuvant DBD and BCNU in cycles of six weeks for a maximum total treatment duration of one year. OS was the primary end-point. RESULTS: Patients (193 ) with newly diagnosed AA according to local pathological assessment were randomised to radiotherapy (RT) alone (n=99), or to RT plus DBD/BCNU (n=94); 12 patients were considered not eligible. At central pathology review, over half (53%) of the locally diagnosed AA cases could not be confirmed. On intent-to-treat analysis, no statistically significant differences in OS (p=0.111) and PFS (p=0.087) were observed, median OS after RT was only 23.9 months 95% confidence interval (CI), [18.4-34.0] after RT plus DBD/BCNU 27.3 months 95% CI [21.4-46.8]. CONCLUSION: No statistically significant improvement in survival was observed after BCNU/DBD adjuvant chemotherapy in AA patients. The trend towards improved survival is consistent with previous reports. Central pathology review of grade 3 tumours remains crucial.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Astrocitoma/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Astrocitoma/radioterapia
Carmustina/administração & dosagem
Carmustina/efeitos adversos
Quimioterapia Adjuvante
Feminino
Doenças Hematológicas/induzido quimicamente
Seres Humanos
Estimativa de Kaplan-Meier
Masculino
Meia-Idade
Mitolactol/administração & dosagem
Mitolactol/efeitos adversos
Falha de Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
LJ2P1SIK8Y (Mitolactol); U68WG3173Y (Carmustine)
[Em] Mês de entrada:0809
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:080206
[St] Status:MEDLINE
[do] DOI:10.1016/j.ejca.2007.12.005


  7 / 183 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:17152492
[Au] Autor:Wei L; Song XR; Wang XW; Li M; Z uo WS
[Ad] Endereço:Cancer Research Center of Shandong Tumor Hospital, Jinan 250117, China.
[Ti] Título:[Expression of MDR1 and GST-pi in osteosarcoma and soft tissue sarcoma and their correlation with chemotherapy resistance].
[So] Source:Zhonghua Zhong Liu Za Zhi;28(6):445-8, 2006 Jun.
[Is] ISSN:0253-3766
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:OBJECTIVE: To explore the expression of multidrug resistance gene 1 ( MDR1), glutathione-S-transferases-pi (GST-pi) in osteosarcoma and soft tissue sarcoma tissues from 34 patients and their correlation with chemotherapy resistance. METHODS: MDR1 and GST-pi expressions were analyzed by real-time fluorescence quantitative polymerase chain reaction (FQ-PCR) and flow cytometry (FCM) at mRNA and protein levels, respectively. Chemotherapy sensitivity on adriamycin, cisplatinum, fluorouracil, mitomycin C, dacarbazine, vincristine, methotrexate in tumor tissues were detected by MTT assay. RESULTS: The nonsensitive rates on adriamycin, cisplatinum, fluorouracil, mitomycin C, dacarbazine, vincristine, methotrexate in tumor tissues were 41.18%, 17.7%, 47.1%, 50.0%, 76.5%, 61.8% and 52.9%, respectively. The expression of P-glycoprotein (P-gp) and GST-pi in tumor tissues was 1.54 and 2.58 (relative fluorescence intensity). Chi2 analysis showed that there was a positive correlation between P-gp expression and drug resistance on ADM, GST-pi expression and resistance on ADM, DDP and MMC (P < 0.05). There was not seen obvious correlation between expression of MDR1, GST-pi and age, gender, pathological type, tumor size in osteosarcoma and soft tissue sarcoma patients (P > 0.05). The expression of GST-pi was increased in patients receiving preoperative chemotherapy. The rate of postoperative recurrence was higher in patients with higher GST-pi expression level than those with lower GST-pi expression level before operation (P < 0.05). CONCLUSION: Individual differences exist in chemotherapy sensitivity and expression of MDR1 and GST-pi in osteosarcoma and soft tissue sarcomas patients. Chemotherapy can induce up-regulation of GST-pi protein expression. Primary high expression of GST-pi is the main mechanism of resistance of osteosarcoma and soft tissue sarcomas to chemotherapy and is related to poor prognosis.
[Mh] Termos MeSH primário: Membro 1 da Subfamília B de Cassetes de Ligação de ATP/biossíntese
Neoplasias Ósseas/metabolismo
Glutationa S-Transferase pi/biossíntese
Osteossarcoma/metabolismo
Sarcoma/metabolismo
[Mh] Termos MeSH secundário: Membro 1 da Subfamília B de Cassetes de Ligação de ATP/genética
Adolescente
Adulto
Idoso
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Neoplasias Ósseas/tratamento farmacológico
Neoplasias Ósseas/genética
Criança
Cisplatino/uso terapêutico
Doxorrubicina/uso terapêutico
Resistência a Múltiplos Medicamentos
Resistência a Medicamentos Antineoplásicos
Feminino
Citometria de Fluxo
Seguimentos
Glutationa S-Transferase pi/genética
Seres Humanos
Masculino
Meia-Idade
Mitolactol/uso terapêutico
Mitomicinas/uso terapêutico
Osteossarcoma/tratamento farmacológico
Osteossarcoma/genética
Prognóstico
RNA Mensageiro/biossíntese
RNA Mensageiro/genética
Reação em Cadeia da Polimerase Via Transcriptase Reversa/métodos
Sarcoma/tratamento farmacológico
Sarcoma/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (ATP-Binding Cassette, Sub-Family B, Member 1); 0 (Mitomycins); 0 (RNA, Messenger); 80168379AG (Doxorubicin); EC 2.5.1.18 (Glutathione S-Transferase pi); LJ2P1SIK8Y (Mitolactol); Q20Q21Q62J (Cisplatin)
[Em] Mês de entrada:0802
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:061213
[St] Status:MEDLINE


  8 / 183 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
[PMID]:16254147
[Au] Autor:Becton D; Dahl GV; Ravindranath Y; Chang MN; Behm FG; Raimondi SC; Head DR; Stine KC; Lacayo NJ; Sikic BI; Arceci RJ; Weinstein H; Pediatric Oncology Group
[Ad] Endereço:University of Arkansas for Medical Sciences, Little Rock, USA.
[Ti] Título:Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421.
[So] Source:Blood;107(4):1315-24, 2006 Feb 15.
[Is] ISSN:0006-4971
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Relapse is a major obstacle in the cure of acute myeloid leukemia (AML). The Pediatric Oncology Group AML Study 9421 tested 2 different strategies to improve event-free survival (EFS) and overall survival (OS). Patients were randomized to receive standard-dose DAT (daunorubicin, cytarabine, and thioguanine) or high-dose DAT during induction. To interfere with P-glycoprotein (P-gp)-dependent drug efflux, the second randomization tested the benefit of cyclosporine (CsA) added to consolidation chemotherapy. Of the 282 children randomly assigned to receive standard DAT induction, 248 (87.9%) achieved remission compared to 253 (91%) of the 278 receiving high-dose DAT (P = ns). Children with HLA-identical sibling donors who achieved a complete remission received an allogeneic bone marrow transplant as consolidation. For the 83 patients receiving a matched related donor bone marrow transplantation (BMT), the 3-year disease-free survival (DFS) is 67%. Of the 418 children who achieved remission and went on to consolidation with and without CsA, the DFS was 40.6% and 33.9%, respectively (P = .24). Overexpression of P-gp was infrequent (14%) in this pediatric population. In this study, intensifying induction with high-dose DAT and the addition of CsA to consolidation chemotherapy did not prolong the durations of remission or improve overall survival for children with AML.
[Mh] Termos MeSH primário: Membro 1 da Subfamília B de Cassetes de Ligação de ATP/efeitos dos fármacos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Ciclosporina/uso terapêutico
Leucemia Mieloide Aguda/tratamento farmacológico
[Mh] Termos MeSH secundário: Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
Criança
Pré-Escolar
Intervalo Livre de Doença
Doxorrubicina/administração & dosagem
Feminino
Seres Humanos
Imunossupressores/uso terapêutico
Lactente
Cariotipagem
Contagem de Leucócitos
Masculino
Mitolactol/administração & dosagem
Indução de Remissão
Análise de Sobrevida
Tamoxifeno/administração & dosagem
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (ATP-Binding Cassette, Sub-Family B, Member 1); 0 (Immunosuppressive Agents); 094ZI81Y45 (Tamoxifen); 80168379AG (Doxorubicin); 83HN0GTJ6D (Cyclosporine); LJ2P1SIK8Y (Mitolactol)
[Em] Mês de entrada:0604
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:051029
[St] Status:MEDLINE


  9 / 183 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:15330214
[Au] Autor:Olasz L; Nyárády Z; Németh A; Királyfalvi L; Ember I
[Ad] Endereço:Department of Oral and Maxillofacial Surgery, University Pécs, Dischka Gy. u 5., Pécs H-7621, Hungary. lajos.olasz@aok.pte.hu
[Ti] Título:Failure of alkylating agents to improve induction chemotherapy of oropharyngeal squamous cell cancer.
[So] Source:Anticancer Res;24(4):2557-61, 2004 Jul-Aug.
[Is] ISSN:0250-7005
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: This prospective semi-randomized study was undertaken to assess the effects and effectiveness of alkylating drugs in a preoperative setting. PATIENTS AND METHODS: During a 6-year period preceding February 2000, 80 patients with Stage II-IVa (AJCC 2002) squamous cell cancer of the oral cavity were treated. Thirty patients (Group N) received a combination of bleomycin, vincristine and methotrexate (BVM). In the alkylating group, thirty patients (Group A/M) received BVM and mitolactol (dibromodulcitol), while twenty patients (Group A/C) received BVM and cisplatin. Patients underwent surgery within 3 weeks after chemotherapy. Clinical response rate and tumour-free survival were investigated. RESULTS: Clinical complete response was 30%-36% (Group N-A). Partial response was 57%-56% (Group N-A). Side-effects were moderate and reversible. Nausea, anaemia and leucopenia were observed in the alkylating (A) group, while other side-effects (alopecia, mucositis, gastritis) were similar in both groups. The observation time was 36 months. Regional disease-free survival showed a significant difference, favouring the non-alkylating (N) group (p=0.03). A higher metastasis rate was observed in the alkylating (A) group. CONCLUSION: Cisplatin and mitolactol in combination with BVM showed higher local control and lower disease-free survival than BVM alone. That was mostly due to a higher rate of regional metastatis formation in the alkylating-treated patients. This may be a late side-effect caused by the immunosuppressive and myelosuppressive effect of alkylating agents.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Carcinoma de Células Escamosas/tratamento farmacológico
Neoplasias Orofaríngeas/tratamento farmacológico
[Mh] Termos MeSH secundário: Antineoplásicos Alquilantes/administração & dosagem
Antineoplásicos Alquilantes/efeitos adversos
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Bleomicina/administração & dosagem
Bleomicina/efeitos adversos
Cisplatino/administração & dosagem
Cisplatino/efeitos adversos
Intervalo Livre de Doença
Feminino
Seres Humanos
Masculino
Metotrexato/administração & dosagem
Metotrexato/efeitos adversos
Meia-Idade
Mitolactol/administração & dosagem
Mitolactol/efeitos adversos
Estudos Prospectivos
Falha de Tratamento
Vincristina/administração & dosagem
Vincristina/efeitos adversos
[Pt] Tipo de publicação:CLINICAL TRIAL; COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antineoplastic Agents, Alkylating); 11056-06-7 (Bleomycin); 5J49Q6B70F (Vincristine); LJ2P1SIK8Y (Mitolactol); Q20Q21Q62J (Cisplatin); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:0409
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:040828
[St] Status:MEDLINE


  10 / 183 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:14532995
[Au] Autor:Nakamura T; Kato Y; Fuji H; Horiuchi T; Chiba Y; Tanaka K
[Ad] Endereço:Second Department of Surgery, Fukui Medical University, Matsuoka-Cho, Yoshida-Gun, Fukui 910-1193, Japan. tomoaki@fmsrsa.fukui-med.ac.jp
[Ti] Título:E-cadherin-dependent intercellular adhesion enhances chemoresistance.
[So] Source:Int J Mol Med;12(5):693-700, 2003 Nov.
[Is] ISSN:1107-3756
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:E-cadherin, an intercellular adhesion molecule, is important in cell growth and differentiation. Adhesion between cells is thought to decrease as cancers develop and disseminate. Knowledge of the effect of cell adhesion on proliferation and chemosensitivity may help individualize cancer treatment. Lovo and MCF-7 cells, which express E-cadherin, and PC-3 cells, which do not, were used in this study. Proliferation and chemosensitivity were measured in two-dimensional (2-D) culture and three-dimensional (3-D) culture. Protein and mRNA expression of E-cadherin, catenin, and cyclin-dependent kinase inhibitors were determined. Growth of Lovo and MCF-7 but not PC-3 cells was markedly suppressed in 3-D relative to 2-D. MCF-7 cells express high levels for E-cadherin, catenin, and p27 in 3-D, but catenin and p27 expression was decreased by exposure to anti-E-cadherin neutralizing antibody. Chemosensitivity of PC-3 was similar in 2-D and 3-D, but chemosensitivity of Lovo and MCF-7 was less in 3-D than 2-D. Moreover, the presence of anti-E-cadherin antibody increased chemosensitivity of MCF-7 in 3-D. E-cadherin affected the regulation of cell proliferation and differentiation, and decreased chemosensitivity. Chemosensitivity of cancer is affected by the state of cell adhesion and expression of intercellular adhesion molecules. Consideration of intercellular adherence characteristics in different chemosensitivity tests is likely to improve their reliability.
[Mh] Termos MeSH primário: Caderinas/metabolismo
Resistência a Medicamentos Antineoplásicos
[Mh] Termos MeSH secundário: Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia
Apoptose/efeitos dos fármacos
Caderinas/genética
Adesão Celular/efeitos dos fármacos
Proteínas de Ciclo Celular/antagonistas & inibidores
Proteínas de Ciclo Celular/metabolismo
Divisão Celular/efeitos dos fármacos
Linhagem Celular Tumoral
Tamanho Celular
Cisplatino/farmacologia
Inibidor de Quinase Dependente de Ciclina p21
Inibidor de Quinase Dependente de Ciclina p27
Inibidor de Quinase Dependente de Ciclina p57
Quinases Ciclina-Dependentes/antagonistas & inibidores
Ciclinas/antagonistas & inibidores
Ciclinas/metabolismo
Proteínas do Citoesqueleto/metabolismo
Doxorrubicina/farmacologia
Inibidores Enzimáticos/metabolismo
Inibidores Enzimáticos/farmacologia
Fluoruracila/farmacologia
Seres Humanos
Concentração Inibidora 50
Mitolactol/farmacologia
Mitomicinas/farmacologia
Proteínas Nucleares/antagonistas & inibidores
Proteínas Nucleares/metabolismo
RNA Mensageiro/genética
RNA Mensageiro/metabolismo
Transativadores/metabolismo
Proteínas Supressoras de Tumor/antagonistas & inibidores
Proteínas Supressoras de Tumor/metabolismo
alfa Catenina
beta Catenina
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (CDKN1A protein, human); 0 (CDKN1C protein, human); 0 (CTNNA1 protein, human); 0 (CTNNB1 protein, human); 0 (Cadherins); 0 (Cell Cycle Proteins); 0 (Cyclin-Dependent Kinase Inhibitor p21); 0 (Cyclin-Dependent Kinase Inhibitor p57); 0 (Cyclins); 0 (Cytoskeletal Proteins); 0 (Enzyme Inhibitors); 0 (Mitomycins); 0 (Nuclear Proteins); 0 (RNA, Messenger); 0 (Trans-Activators); 0 (Tumor Suppressor Proteins); 0 (alpha Catenin); 0 (beta Catenin); 147604-94-2 (Cyclin-Dependent Kinase Inhibitor p27); 80168379AG (Doxorubicin); EC 2.7.11.22 (Cyclin-Dependent Kinases); LJ2P1SIK8Y (Mitolactol); Q20Q21Q62J (Cisplatin); U3P01618RT (Fluorouracil)
[Em] Mês de entrada:0407
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:031009
[St] Status:MEDLINE



página 1 de 19 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde